- Generative AI antibody design with wet lab
- Built specifically for drug discovery teams, not bolt-on AI
- Scales to organization-wide healthcare rollouts
Absci
Generative AI antibody design with wet lab
SF7.5
SF Score editorial score across features, ease, and value, based on public reviews and product research. Learn more →
Support protein engineering programsPharma partners and biologics teams
Support protein engineering programsPharma partners and biologics teams
Best for
Pharma partners and biologics teams
Pricing
Custom
SoftFinders Score
7.5 / 10
Overview
What is Absci?
Absci is a generative AI drug discovery platform for pharma and biologics teams, designing antibodies and therapeutics through integrated AI and wet-lab data.
- Research focus: It supports R&D acceleration and computational biology rather than guaranteed clinical outcomes, with candidates requiring downstream validation and trials.
- Best-fit environment: Pharma partners and biologics teams fit best when generative antibody design aligns with discovery and wet-lab workflows.
- Engagement model: Access runs through pharma partnership deals rather than self-service subscriptions, making collaboration structure, data requirements, and validated-lead timelines considerations.
- Commercial model: Pricing is sales-led and scoped per buyer rather than publicly posted, with economics shaped by scope.
Absci is best assessed as a partnership-led antibody discovery platform whose fit depends on scientific objectives, wet-lab integration, and program economics.
KEY FEATURES
What you get out of the box
Protein Modeling
Predicts and designs protein structures
Knowledge Graph
Connects biological and chemical knowledge sources
Virtual Screening
Screens compound libraries against targets
Literature Intelligence
Mines biomedical literature for relevant evidence
Multi Omics
Integrates genomic and other omics data sources
Lab Integration
Connects discovery insights with wet-lab workflows
USE CASES
Where teams put it to work
Support protein engineering programs
Mine literature for research signals
Run virtual screens against targets
Collaborate with pharma partners
Bridge AI design and wet lab cycles
Identify drug targets from biology data
Editorial Take
What we like, and what to verify
- Engagement runs through partnership deals
- Drug success still depends on downstream trials
- Pricing is sales-led and needs scoping upfront
Screenshots
A look inside
Alternatives
Tools to consider next
Iktos SF 7.4
Why consider it
Generative chemistry and synthesis planning AI
Cradle SF 7.5
Why consider it
AI protein design for wet labs
Chai Discovery SF 7.3
Why consider it
Molecular structure prediction for discovery research
NOETIK SF 7.1
Why consider it
Spatial biology models for cancer targets
Generate Biomedicines SF 7.7
Why consider it
Generative protein design across modalities
Causaly SF 7.6
Why consider it
Biomedical evidence and reasoning for R&D
FAQ